CALGARY, ABLBERTA -- (MARKET WIRE) -- January 30, 2007 -- Resverlogix Corp. (“Resverlogix”) (TSX: RVX), is pleased to announce today that it has named Drs. Daniel Rader, M.D. and Jacques Genest, M.D., both internationally renowned cardiovascular researchers, to Resverlogix’s Clinical Review Committee.
